This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuchs, P. C.
Right arrow Articles by Brown, S. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuchs, P. C.
Right arrow Articles by Brown, S. D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2001, p. 1915-1918, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1915-1918.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

In Vitro Activities of Ertapenem (MK-0826) against Clinical Bacterial Isolates from 11 North American Medical Centers

Peter C. Fuchs,* Arthur L. Barry, and Steven D. Brown

The Clinical Microbiology Institute, Wilsonville, Oregon 97070

Received 8 August 2000/Returned for modification 17 December 2000/Accepted 8 March 2001

This study compared the in vitro activities of the new long-half-life carbapenem ertapenem (also known as MK-0826 and L-749,345) with those of imipenem, amoxicillin-clavulanate, and ciprofloxacin against 5,558 recent clinical isolates from 11 North American medical centers. We confirmed the greater activity of ertapenem than of imipenem against the Enterobacteriaceae and the greater activity of imipenem against pseudomonads and gram-positive bacteria.

* Corresponding author. Mailing address: Clinical Microbiology Institute, 9725 SW Commerce Circle, Wilsonville, OR 97070. Phone: (503) 682-3232. Fax: (503) 682-2065. E-mail: cmi{at}hevanet.com.

Antimicrobial Agents and Chemotherapy, June 2001, p. 1915-1918, Vol. 45, No. 6
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.6.1915-1918.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Burkhardt, O., Brunner, M., Schmidt, S., Grant, M., Tang, Y., Derendorf, H. (2006). Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 58: 632-636 [Abstract] [Full Text]  
  • Ling, T. K. W., Xiong, J., Yu, Y., Lee, C. C., Ye, H., Hawkey, P. M., The MK0826 China Study Group, (2006). Multicenter Antimicrobial Susceptibility Survey of Gram-Negative Bacteria Isolated from Patients with Community-Acquired Infections in the People's Republic of China. Antimicrob. Agents Chemother. 50: 374-378 [Abstract] [Full Text]  
  • Fish, D. N., Teitelbaum, I., Abraham, E. (2005). Pharmacokinetics and Pharmacodynamics of Imipenem during Continuous Renal Replacement Therapy in Critically Ill Patients. Antimicrob. Agents Chemother. 49: 2421-2428 [Abstract] [Full Text]  
  • Burkhardt, O., Majcher-Peszynska, J., Borner, K., Mundkowski, R., Drewelow, B., Derendorf, H., Welte, T. (2005). Penetration of Ertapenem Into Different Pulmonary Compartments of Patients Undergoing Lung Surgery. J Clin Pharmacol 45: 659-665 [Abstract] [Full Text]  
  • Livermore, D. M., Mushtaq, S., Warner, M. (2005). Selectivity of ertapenem for Pseudomonas aeruginosa mutants cross-resistant to other carbapenems. J Antimicrob Chemother 55: 306-311 [Abstract] [Full Text]  
  • Jacoby, G. A., Mills, D. M., Chow, N. (2004). Role of {beta}-Lactamases and Porins in Resistance to Ertapenem and Other {beta}-Lactams in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48: 3203-3206 [Abstract] [Full Text]  
  • Alhambra, A., Cuadros, J. A., Cacho, J., Gomez-Garces, J. L., Alos, J. I. (2004). In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 53: 1090-1094 [Abstract] [Full Text]  
  • Livermore, D. M., Sefton, A. M., Scott, G. M. (2003). Properties and potential of ertapenem. J Antimicrob Chemother 52: 331-344 [Abstract] [Full Text]  
  • Gesser, R. M., McCarroll, K., Teppler, H., Woods, G. L. (2003). Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data. J Antimicrob Chemother 51: 1253-1260 [Abstract] [Full Text]  
  • Kato, N., Yamazoe, K., Han, C.-G., Ohtsubo, E. (2003). New Insertion Sequence Elements in the Upstream Region of cfiA in Imipenem-Resistant Bacteroides fragilis Strains. Antimicrob. Agents Chemother. 47: 979-985 [Abstract] [Full Text]  
  • Pelak, B. A., Citron, D. M., Motyl, M., Goldstein, E. J. C., Woods, G. L., Teppler, H. (2002). Comparative in vitro activities of ertapenem against bacterial pathogens from patients with acute pelvic infection. J Antimicrob Chemother 50: 735-741 [Abstract] [Full Text]  
  • Tomera, K. M., Burdmann, E. A., Reyna, O. G. P., Jiang, Q., Wimmer, W. M., Woods, G. L., Gesser, R. M. (2002). Ertapenem versus Ceftriaxone Followed by Appropriate Oral Therapy for Treatment of Complicated Urinary Tract Infections in Adults: Results of a Prospective, Randomized, Double-Blind Multicenter Study. Antimicrob. Agents Chemother. 46: 2895-2900 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»